Close Menu

NEW YORK (GenomeWeb News) – MolecularMD today announced a licensing deal covering DDR2 mutations for lung cancer.

The Portland, Ore.-based company has obtained the rights to commercialize IP around the mutations for diagnostic, prognostic, and predictive uses. The IP is jointly owned by the Broad Institute and Dana-Farber Cancer Institute.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.